Precision BioSciences, Inc. (DTIL) News
Filter DTIL News Items
DTIL News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
DTIL News Highlights
- DTIL's 30 day story count now stands at 5.
- Over the past 25 days, the trend for DTIL's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about DTIL are GENE and RARE.
Latest DTIL News From Around the Web
Below are the latest news stories about PRECISION BIOSCIENCES INC that investors may wish to consider to help them evaluate DTIL as an investment opportunity.
Precision BioSciences to Participate in Upcoming Guggenheim Healthcare Talks ConferenceDURHAM, N.C., March 27, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that the Company will participate in the Guggenheim Healthcare Talks – Genomic Medicines and Rare Disease Days taking place April 3-4, 2023. |
Precision BioSciences (DTIL) Reports Q4 Loss, Tops Revenue EstimatesPrecision BioSciences (DTIL) delivered earnings and revenue surprises of -8.33% and 78%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock? |
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business UpdateDURHAM, N.C., March 09, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced financial results for the fourth quarter and fiscal year ended December 31, 2022 and provided a business update. |
A Precision BioSciences, Inc. (NASDAQ:DTIL) insider increased their holdings by 38% last yearInsiders were net buyers of Precision BioSciences, Inc.'s ( NASDAQ:DTIL ) stock during the past year. That is, insiders... |
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2022 Results on March 9, 2023DURHAM, N.C., March 02, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that it will publish financial results for the fourth quarter and fiscal year 2022 and provide a business update on March 9, 2023. |
Precision BioSciences Announces Senior Leadership Promotions and Organizational ChangesDURHAM, N.C., February 24, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced a promotion and organizational changes within the Company’s Senior Leadership Team (SLT). |
Precision BioSciences to Participate in Upcoming H.C. Wainwright Cell Therapy Virtual ConferenceDURHAM, N.C., February 22, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that the Company will participate in the H.C. Wainwright Cell Therapy Virtual Conference taking place February 28, 2023. |
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)DURHAM, N.C., February 14, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that, on February 9, 2023, the Compensation Committee of Precision’s Board of Directors approved the grant of inducement awards to new employees under the Precision BioSciences, Inc. 2021 Employment Inducement Incentive Award Plan ("Inducement Award Plan"). The inducement awards cons |
Shareholders in Precision BioSciences (NASDAQ:DTIL) have lost 88%, as stock drops 11% this past weekPrecision BioSciences, Inc. ( NASDAQ:DTIL ) shareholders should be happy to see the share price up 15% in the last... |
Precision BioSciences Recaps 2022 Accomplishments and Outlines 2023 Corporate Priorities and Planned Portfolio MilestonesDURHAM, N.C., January 09, 2023--Precision BioSciences (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today reported on its significant accomplishments in 2022 and announced its corporate priorities and anticipated clinical development and research milestones for 2023. |